Climaco John M — SEC insider filings
SEC reporting owner CIK 1546797. 17 insider filings on record with FilingPulse; latest filed 2026-11-19.
Transaction summary — filings shown
Covers all 17 filings on record, filed 2021-02-09 to 2026-11-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 184,416 shares, $65,353 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
- Largest priced transaction: purchase of 166,666 shares @ $0.30 ($50,000) in CNS Pharmaceuticals, Inc., filed 2024-02-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | Chief Executive Officer, Director | 11 | 3 legs · 184,416 sh · $65,353 | — | 12 |
| Moleculin Biotech, Inc. (MBRX) | Director | 6 | — | — | 7 |
Insider filings — Climaco John M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Moleculin Biotech, Inc. (MBRX) | Grant/award (A): 4,000 (derivative) | EDGAR |
| 2025-11-19 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Grant/award (A): 9,761 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | Moleculin Biotech, Inc. (MBRX) | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2024-11-06 | 4 | Moleculin Biotech, Inc. (MBRX) | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2024-04-10 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Grant/award (A): 83,000 (derivative) · Grant/award (A): 83,000 (derivative) | EDGAR |
| 2024-02-06 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Purchase (P): 166,666 @ $0.30 · Grant/award (A): 166,666 (derivative) · Grant/award (A): 166,666 (derivative) | EDGAR |
| 2023-08-16 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Purchase (P): 2,750 @ $1.80 | EDGAR |
| 2023-05-26 | 4 | Moleculin Biotech, Inc. (MBRX) | Grant/award (A): 15,000 (derivative) | EDGAR |
| 2023-05-01 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Option exercise (M): 1,250 · Option exercise (M): 1,250 (derivative) | EDGAR |
| 2023-04-14 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Purchase (P): 15,000 @ $0.69 | EDGAR |
| 2023-03-31 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Grant/award (A): 16,467 (derivative) | EDGAR |
| 2022-06-22 | 4 | Moleculin Biotech, Inc. (MBRX) | Grant/award (A): 23,333 (derivative) · Grant/award (A): 15,000 (derivative) | EDGAR |
| 2022-04-29 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Grant/award (A): 600,000 (derivative) | EDGAR |
| 2022-03-08 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Grant/award (A): 35,000 @ $0.28 | EDGAR |
| 2021-11-18 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Grant/award (A): 5,000 @ $1.28 | EDGAR |
| 2021-06-09 | 4 | Moleculin Biotech, Inc. (MBRX) | Grant/award (A): 10,000 (derivative) | EDGAR |
| 2021-02-09 | 4 | CNS Pharmaceuticals, Inc. (CNSP) | Grant/award (A): 310,000 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1546797 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs